Overall, our results highlight that promoting PRL/PRLR signaling while inhibiting the YAP-CCN2 oncogenic pathway as a differentiation-based therapeutic opportunity in breast cancer with potential merit in other cancers. This evidence concerns the gene YAP1 and cancer.